Insufficient scRNA-seq data for expression of PLEKHN1 at single-cell level.
Insufficient scRNA-seq data for expression of PLEKHN1 at tissue level.
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
prostate | 69% | 427.25 | 170 / 245 | 90% | 4.94 | 451 / 502 |
bladder | 57% | 834.29 | 12 / 21 | 88% | 13.46 | 441 / 504 |
esophagus | 39% | 2037.17 | 558 / 1445 | 91% | 11.13 | 167 / 183 |
breast | 43% | 202.80 | 196 / 459 | 85% | 5.12 | 949 / 1118 |
skin | 78% | 3347.55 | 1419 / 1809 | 31% | 1.57 | 145 / 472 |
ureter | 0% | 0 | 0 / 0 | 100% | 10.94 | 1 / 1 |
lung | 10% | 32.97 | 57 / 578 | 85% | 6.92 | 979 / 1155 |
pancreas | 5% | 24.34 | 18 / 328 | 87% | 9.98 | 154 / 178 |
kidney | 29% | 150.64 | 26 / 89 | 63% | 4.12 | 565 / 901 |
tonsil | 0% | 0 | 0 / 0 | 91% | 8.96 | 41 / 45 |
stomach | 10% | 39.11 | 35 / 359 | 78% | 4.41 | 222 / 286 |
intestine | 2% | 7.30 | 21 / 966 | 78% | 5.05 | 412 / 527 |
uterus | 3% | 52.18 | 5 / 170 | 77% | 9.87 | 354 / 459 |
thymus | 6% | 23.08 | 41 / 653 | 73% | 6.94 | 443 / 605 |
ovary | 0% | 0 | 0 / 180 | 66% | 3.70 | 285 / 430 |
liver | 4% | 17.85 | 8 / 226 | 20% | 1.03 | 80 / 406 |
adrenal gland | 17% | 64.79 | 44 / 258 | 4% | 0.23 | 9 / 230 |
eye | 0% | 0 | 0 / 0 | 14% | 0.43 | 11 / 80 |
spleen | 7% | 22.99 | 18 / 241 | 0% | 0 | 0 / 0 |
lymph node | 0% | 0 | 0 / 0 | 3% | 0.07 | 1 / 29 |
peripheral blood | 2% | 6.31 | 18 / 929 | 0% | 0 | 0 / 0 |
muscle | 1% | 5.33 | 11 / 803 | 0% | 0 | 0 / 0 |
brain | 0% | 0 | 0 / 2642 | 1% | 0.11 | 6 / 705 |
blood vessel | 1% | 4.42 | 10 / 1335 | 0% | 0 | 0 / 0 |
adipose | 1% | 3.60 | 9 / 1204 | 0% | 0 | 0 / 0 |
heart | 0% | 0.79 | 2 / 861 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
GO_0043065 | Biological process | positive regulation of apoptotic process |
GO_0001666 | Biological process | response to hypoxia |
GO_0061158 | Biological process | 3'-UTR-mediated mRNA destabilization |
GO_0031966 | Cellular component | mitochondrial membrane |
GO_0005856 | Cellular component | cytoskeleton |
GO_0005886 | Cellular component | plasma membrane |
GO_0005739 | Cellular component | mitochondrion |
GO_0070300 | Molecular function | phosphatidic acid binding |
GO_1901612 | Molecular function | cardiolipin binding |
GO_0001786 | Molecular function | phosphatidylserine binding |
GO_0005515 | Molecular function | protein binding |
GO_1901981 | Molecular function | phosphatidylinositol phosphate binding |
Gene name | PLEKHN1 |
Protein name | Pleckstrin homology domain containing N1 Pleckstrin homology domain-containing family N member 1 (PH domain-containing family N member 1) (Cardiolipin and phosphatidic acid-binding protein) |
Synonyms | CLPABP |
Description | FUNCTION: Controls the stability of the leptin mRNA harboring an AU-rich element (ARE) in its 3' UTR, in cooperation with the RNA stabilizer ELAVL1 . Decreases the stability of the leptin mRNA by antagonizing the function of ELAVL1 by inducing its atypical recruitment from the nucleus to the cytosol (By similarity). Binds to cardiolipin (CL), phosphatidic acid (PA), phosphatidylinositol 4-phosphate (PtdIns(4)P) and phosphatidylserine (PS) . Promotes apoptosis by enhancing BAX-BAK hetero-oligomerization via interaction with BID in colon cancer cells (By similarity). . |
Accessions | ENST00000491024.1 ENST00000379407.7 [Q494U1-3] ENST00000379410.8 [Q494U1-1] ENST00000379409.6 [Q494U1-2] J3KSM5 Q494U1 |